Cabaletta Bio (NASDAQ: CABA) — Company Overview, News & Financial Data
Cabaletta Bio develops T-cell therapies aimed at providing functional cures for autoimmune diseases.
Cabaletta Bio
Cabaletta Bio (NASDAQ:CABA) focuses on developing therapies aimed at providing a functional cure for patients with autoimmune diseases. Its approach centers on utilizing engineered T cell therapies targeting B cell-mediated autoimmune diseases, leveraging its proprietary technology to specifically target and eliminate the cells responsible for disease activity. The company's pipeline includes several projects at various stages of development, targeting a range of autoimmune disorders with the objective of achieving long-term disease remission or functional cure. Cabaletta Bio aims to transform the treatment landscape for autoimmune disease patients, offering new hope through innovative, targeted therapies.
Snapshot
Operations
Products and/or services of Cabaletta Bio
- DesCAARTes™ platform harnesses Chimeric AutoAntibody Receptor T cells designed to target and eliminate B cells causing autoimmune diseases.
- Dsg3-CAART is a therapy aimed at treating mucosal pemphigus vulgaris by selectively targeting and depleting disease-causing B cells.
- FVIII-CAART seeks to provide a potential treatment for hemophilia A by using engineered T cells to eliminate inhibitors of factor VIII.
- MuSK-CAART therapy is being developed for patients with MuSK myasthenia gravis, targeting specific B cells to alleviate symptoms.
- The collaboration with the University of Pennsylvania explores novel CAART therapies for autoimmune diseases by leveraging genetic engineering expertise and clinical insights.
- CART-TT focuses on T cell-mediated therapies to potentially treat T cell-related autoimmune and inflammatory diseases, offering a unique approach by targeting specific T cell subsets.
Cabaletta Bio executive team
- Steven A. NichtbergerCo-Founder, Chairman, CEO & President
- David J. ChangChief Medical Officer
- Gwendolyn K. BinderPresident of Science & Technology
- Michael C. MiloneCo-Founder & Co-Chair of Scientific Advisory Board
- Aimee PayneCo-Founder & Co-Chair of Scientific Advisory Board
- Anup MardaChief Financial Officer
- Qing Sarah YuanChief Technology Officer
- Samik BasuChief Scientific Officer
- Michael GerardGeneral Counsel & Secretary
- Heather Harte-HallChief Compliance Officer
Key financials
Reported results for Cabaletta Bio, in USD.
- Market cap
- 242.4M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.5
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -172.2M | -167.9M | |
| 0 | -125.1M | -115.9M | |
| 0 | -74.7M | -67.7M | |
| 0 | -54.1M | -51.8M |